Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/cr0ph/staging.phastar.com/wp-includes/functions.php on line 6260
Enhancing Data Oversight - Phastar's Strategic Support
Abstract spiral tunnel representing data management oversight

CRO Oversight: Restoring Quality to Outsourced Oncology and Rheumatology Studies

1 minute read

Published: July 16th, 2025

After acquiring a biotech, a global pharma company faced major issues with two ongoing pharmacokinetic studies—both fully outsourced and poorly managed. Lack of CRO oversight had led to data inconsistencies, missed deadlines, and quality concerns.

Phastar was brought in to take control. By providing targeted CRO oversight, identifying critical data issues, and driving process improvements, we helped deliver an on-time database lock and restored confidence in the studies.

In the full case study, you’ll see:

  • The oversight steps taken to regain control
  • How we resolved data quality and reconciliation issues
  • The sponsor’s feedback on Phastar’s impact

Complete the form to download the full case study.

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...